BioSpace News Archive

Press Releases

Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update

January 13, 2025
·
8 min read
Press Releases

Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026

January 13, 2025
·
15 min read
Press Releases

BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)

January 13, 2025
·
8 min read
Press Releases

Rhythm Pharmaceuticals Announces Preliminary Fourth Quarter and Full Year 2024 Net Product Revenues, Pipeline Advancements and Upcoming Milestones

January 13, 2025
·
13 min read
Press Releases

Bio-Path Holdings Provides 2025 Clinical and Operational Update

January 13, 2025
·
9 min read
Press Releases

Immunocore announces strategic priorities at 43rd Annual J.P. Morgan Healthcare Conference

January 13, 2025
·
22 min read
Press Releases

Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

January 13, 2025
·
11 min read
Press Releases

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

January 13, 2025
·
9 min read
Press Releases

Monte Rosa Therapeutics Provides Corporate Update and Key Anticipated Milestones for 2025

January 13, 2025
·
14 min read
Press Releases

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

January 13, 2025
·
4 min read